免疫组化在常规神经病理中识别幕上C11ORF95-RELA融合室管膜瘤的作用
该研究纳入42例幕上室管膜瘤(12例成人,30例儿童),用RT-PCR和Sanger测序确定RELA融合状态,并评估p65/RELA和L1CAM免疫组化预测融合的能力。17例检出RELA融合;p65/RELA免疫组化敏感性100%、特异性92%,L1CAM敏感性94%、特异性76%,双阳性PPV为92.5%且NPV为100%。双阴性可预测无RELA融合,仅单阳性或双阳性病例需分子验证。
要点
- p65/RELA免疫组化预测RELA融合敏感性100%、特异性92%。
- L1CAM免疫组化敏感性94%、特异性76%,NPV 95%。
- 双阴性可预测无RELA融合,单/双阳性需分子验证。
核心结论
- 联合p65/RELA和L1CAM免疫组化有助于幕上室管膜瘤RELA融合诊断,双阴性可预测无融合,单阳性或双阳性需分子验证。
研究设计与样本
- 回顾性研究,纳入42例幕上室管膜瘤(12例成人,30例儿童)的FFPE样本,用RT-PCR和Sanger测序确定RELA融合状态,并评估p65/RELA和L1CAM免疫组化预测价值。
主要发现
- 42例中17例检出RELA融合基因。
- L1CAM免疫组化敏感性94%、特异性76%、PPV 73%、NPV 95%。
- p65/RELA免疫组化敏感性100%、特异性92%、PPV 89.5%、NPV 100%。
- 双免疫组化一致时PPV提高至92.5%,NPV保持100%。
关键数值与推荐
- p65/RELA免疫组化敏感性100%、特异性92%、PPV 89.5%、NPV 100%。
- L1CAM免疫组化敏感性94%、特异性76%、PPV 73%、NPV 95%。
- 双免疫组化一致时PPV 92.5%、NPV 100%。
临床怎么用
- 对幕上室管膜瘤常规行p65/RELA和L1CAM免疫组化,双阴性可预测无RELA融合,单阳性或双阳性病例建议分子检测验证融合转录本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ependymomas (EPs) are tumors of the brain and spinal cord constituting ∼10% of the childhood central nervous system neoplasms and about 30% in children aged <3 years. Their anatomic distribution varies according to the age, with those arising in the supratentorial (ST) compartment, spinal cord being more common in older children and adults, and those at the infratentorial location are more common and occurring more frequently in infants and children. Recently, molecular classification of EP subgroups has been proposed and a supratentorial ependymoma subgroup characterized by RELA-fusion genes (ST-EP-RELA) has been established. It would be useful to define a standardized, robust method for the diagnosis of these relevant fusion genes. We used real-time polymerase chain reaction, conventional real-time polymerase chain reaction, and Sanger sequencing to characterize RELA fusion status in formalin-fixed paraffin-embedded samples from 42 ST-EPs (12 adults and 30 pediatric). We tested p65/RELA and L1CAM protein immunohistochemistry for their ability to predict RELA-fusion status. We reviewed clinical data to assess significant associations in this anatomic subgroup. Of the 42 patients, we identified RELA-fusion genes in 17 cases. L1CAM immunostaining displayed 94% sensitivity, 76% specificity, 73% positive predictive value (PPV), 95% negative predictive value (NPV). The p65/RELA immunostaining displayed 100% sensitivity, 92% specificity, 89.5% PPV, 100% NPV. Concordant double immunostaining improves PPV to 92.5% and maintains 100% NPV. Immunohistochemistry using both p65/RELA and L1CAM antibodies is valuable for ST-EP-RELA diagnosis: the negativity with both antibodies consistently predicts the absence of RELA fusions, whereas verification of fusion transcripts by molecular analyses is warranted only in single-positive or double-positive staining cases.
引用
- Gessi M, Giagnacovo M, Modena P, et al. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology. Am J Surg Pathol. 2019. PMID: 29266023. doi:10.1097/PAS.0000000000000979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。